circulating tumor DNA
Following a lung cancer study, the firm plans to initiate similar studies in other cancers and to launch a new tumor profiling assay later this year.
Observation alone resulted in positive outcomes for MRD-negative patients, whereas MRD-positive individuals may still need adjuvant chemotherapy.
The San Jose, California-based company has developed AccuScan, which analyzes a patient's circulating tumor DNA but does not require bespoke reagents.
BillionToOne Inks $140M Financing Agreement With Oberland Capital
The company said the funds will help it shore up its plans to reach profitability and supplant the need for additional financing rounds.
Foresight Diagnostics Adds $33M to Series B Financing Round
The company has now raised $73.8 million in the round and plans to use the new funding to advance development of its Clarity minimal residual disease assay.
Jun 5, 2024